SKVI), Quoin Pharmaceuticals Merger to Address Opioid Pain Management Market Proposed Skinvisible (SKVI), Quoin Pharmaceuticals Merger to Address Opioid Pain Management Market

SKVI), Quoin Pharmaceuticals Merger to Address Opioid Pain Management Market Proposed Skinvisible (SKVI), Quoin Pharmaceuticals Merger to Address Opioid Pain Management Market
SKVI), Quoin Pharmaceuticals Merger to Address Opioid Pain Management Market Proposed Skinvisible (SKVI), Quoin Pharmaceuticals Merger to Address Opioid Pain Management Market
by is licensed under

A merger between Skinvisible and Quoin Pharmaceuticals will enable a successful entry on the post-surgical pain management marketAging populations and a large number of surgical interventions in the West have contributed to significant market expansion
By 2024, the pain management therapeutics market is expected to reach $83 billion

Skinvisible Pharmaceuticals (OTCQB: SKVI) recently announced that it has signed a Letter of Intent for a proposed merger with Quoin Pharmaceuticals Limited – a partnership that could address significant unmet medical needs on the pain management market. If both parties agree on the terms, the merger should be completed next year, with the resulting entity operating under the name Quoin Pharmaceuticals Inc. and continuing to trade on the OTCQB Venture Market.

Quoin’s strength is within the area of pharmaceutical development for products that address some of the most serious present-day health problems. Skinvisible is the developer of innovative delivery system technologies that can enhance product performance.

Read the full article

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Read More
Tags
Investing, Investing News, Marijuana Investing
Thumbnail Photo Credit: by is licensed under